Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771

Bibliography

• VOGT K, HERMANN J, BLUME U et al.: Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11(10):943-945.
   PubMedGoogle Scholar
• KUROKAWA I, AKAMATSU H, NISHIJIMA S, ASADA Y, KAWABATA S: Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J. Am. Acad. Dermatol. (1991) 25(4):674-681.
   PubMedGoogle Scholar
• DE SOUZA NJ, GUPTE SV, DESHPANDE PK et al.: A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J. Med. Chem. (2005) 48(16):5232-5242.
   Google Scholar
• DRENO B, POLI F: Epidemiology of acne. Dermatology (2003) 206(1):7-10.
   PubMed Web of Science ®Google Scholar
• WHITE GM: Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J. Am. Acad. Dermatol. (1998) 39(2 Pt 3):S34-S37.
   PubMed Web of Science ®Google Scholar
• SMITHARD A, GLAZEBROOK C, WILLIAMS HC: Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br. J. Dermatol. (2001) 145(2):274-279.
   PubMed Web of Science ®Google Scholar
• LAYTON AM: Optimal management of acne to prevent scarring and psychological sequelae. Am. J. Clin. Dermatol. (2001) 2(3):135-141.
   PubMedGoogle Scholar
• MADDEN WS, LANDELLS ID, POULIN Y et al.: Treatment of acne vulgaris and prevention of acne scarring: canadian consensus guidelines. J. Cutan. Med. Surg. (2000) 4(Suppl. 1):S2-13.
   Google Scholar
• ZOUBOULIS CC, PIQUERO-MARTIN J: Update and future of systemic acne treatment. Dermatology (2003) 206(1):37-53.
   Google Scholar
• HAUSTEIN UF, NENOFF P, HITTEL N: Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: clinical evaluation in a multicenter open trial and in vitro antimicrobiologocal susceptibility testing. J. Dermatol. Treatment (1997) 8:87-92.
   Web of Science ®Google Scholar
• NISHIJIMA S, KUROKAWA I, NAKAYA H: Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J. Infect. Chemother (2002) 8(2):187-189.
   PubMedGoogle Scholar
• ASADA Y: Clinical evaluation of nadifloxacin 1% cream in superficial skin infectious diseases caused by bacteria. West Japan Dermatology Separate Print Suppl. (1996) 58(2):1-23.
   Google Scholar
• KIMATA H: Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur. J. Pediatr. (1999) 158(11):949.
   PubMed Web of Science ®Google Scholar
• GUAY DR: Treatment of bacterial skin and skin structure infections. Expert Opin. Pharmacother. (2003) 4(8):1259-1275.
   PubMed Web of Science ®Google Scholar
• HEDRICK J: Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs (2003) 5(Suppl. 1):35-46.
   PubMedGoogle Scholar
• BOUZARI N, NOURI K, TABATABAI H et al.: The role of number of treatments in laser-assisted hair removal using a 755-nm alexandrite laser. J. Drugs Dermatol. (2005) 4(5):573-578.
   Google Scholar
• STEVENS DL, BISNO AL, CHAMBERS HF et al.: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. (2005) 41(10):1373-1406.
   PubMed Web of Science ®Google Scholar
• NENOFF P, HAUSTEIN UF, HITTEL N: Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy (2004) 50(4):196-201.
   PubMedGoogle Scholar
• CORREALE CE, WALKER C, MURPHY L, CRAIG TJ: Atopic dermatitis: a review of diagnosis and treatment. Am. Fam. Physician (1999) 60(4):1191-1198, 1209-1110.
   PubMed Web of Science ®Google Scholar
• KRAUTHEIM A, GOLLNICK HP: Acne: topical treatment. Clin. Dermatol. (2004) 22(5):398-407.
   PubMed Web of Science ®Google Scholar
• KATSAMBAS A, PAPAKONSTANTINOU A: Acne: systemic treatment. Clin. Dermatol. (2004) 22(5):412-418.
   PubMed Web of Science ®Google Scholar
• KATSAMBAS AD, STEFANAKI C, CUNLIFFE WJ: Guidelines for treating acne. Clin. Dermatol. (2004) 22(5):439-444.
   PubMed Web of Science ®Google Scholar
• WYSOWSKI DK, SWANN J, VEGA A: Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J. Am. Acad. Dermatol. (2002) 46(4):505-509.
   PubMedGoogle Scholar
• PARRY MF, RHA CK: Pseudomembranous colitis caused by topical clindamycin phosphate. Arch. Dermatol. (1986) 122(5):583-584.
   PubMed Web of Science ®Google Scholar
• MILSTONE EB, MCDONALD AJ, SCHOLHAMER CF Jr: Pseudomembranous colitis after topical application of clindamycin. Arch. Dermatol. (1981) 117(3):154-155.
   PubMed Web of Science ®Google Scholar
• LEYDEN JJ: A review of the use of combination therapies for the treatment of acne vulgaris. J. Am. Acad. Dermatol. (2003) 49(3 Suppl.):S200-210.
   PubMed Web of Science ®Google Scholar
• BERSON DS, SHALITA AR: The treatment of acne: the role of combination therapies. J. Am. Acad. Dermatol. (1995) 32(5 Pt 3):S31-41.
   Google Scholar
• EADY EA, COVE JH: Topical antibiotic therapy: current status and future prospects. Drugs Exp. Clin. Res. (1990) 16(8):423-433.
   PubMedGoogle Scholar
• APPELBAUM PC, JACOBS MR: Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. (2005) 8(5):510-517.
   PubMed Web of Science ®Google Scholar
• PATEL MV, DE SOUZA NJ, GUPTE SV et al.: Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob. Agents Chemother. (2004) 48(12):4754-4761.
   PubMed Web of Science ®Google Scholar
• KUROKAWA I, NISHIJIMA S, KAWABATA S: Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J. Dermatol. (1999) 9(1):25-28.
   Google Scholar
• YAMAKAWA T, MITSUYAMA J, HAYASHI K: In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. (2002) 49(3):455-465.
   PubMed Web of Science ®Google Scholar
• OIZUMI N, KAWABATA S, HIRAO M et al.: Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J. Infect. Chemother (2001) 7(3):191-194.
   PubMedGoogle Scholar
• JACOBS MR, BAJAKSOUZIAN S, WINDAU A et al.: In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother. (2004) 48(9):3338-3342.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52(5):864-868.
   PubMed Web of Science ®Google Scholar
• HONJO M, WAKUI F, MORISHIMA T et al.: The clinical effect of nadifloxacin (Acuatim Cream) on acne vulgaris and its bacteriological review. West Japan Dermatol. Suppl. (1996) 58(6):1-11.
   Google Scholar
• TANIGUCHI S, CHANOKI M, HAMADA T et al.: Clinical and bacteriologic evaluation of nadifloxacin on acne vulgaris. Rinsho Iyaku (1995) 11(12 Suppl.):1-15.
   Google Scholar
• SARUTA T: Evaluation of a topical new quinolone, acuatim cream, in the treatment of acne vulgaris. Rinsho Iyaku (1995) 11(1 Suppl.):1-16.
   Google Scholar
• NISHIJIMA S, NAMURA S, AKAMATSU H et al.: In vitro activity of nadifloxacin against both methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus from patients with skin infections. Drugs (1995) 49(Suppl. 2):230-232.
   Google Scholar
• VAN BAMBEKE F, MICHOT JM, VAN ELDERE J, TULKENS PM: Quinolones in 2005: an update. Clin. Microbiol. Infect. (2005) 11(4):256-280.
   PubMedGoogle Scholar
• KARCHMER AW: Fluoroquinolone treatment of skin and skin structure infections. Drugs (1999) 58(Suppl. 2):82-84.
   PubMed Web of Science ®Google Scholar
• DOBIE D, GRAY J: Fusidic acid resistance in Staphylococcus aureus. Arch. Dis. Child. (2004) 89(1):74-77.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP, GRAYSON ML: Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. (2006) 42(3):394-400.
   PubMed Web of Science ®Google Scholar
• ZINN CS, WESTH H, ROSDAHL VT: An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb. Drug Resist. (2004) 10(2):160-168.
   PubMed Web of Science ®Google Scholar
• LIVERMORE D, JAMES D, DUCKWORTH G, STEPHENS P: Fusidic-acid use and resistance. Lancet (2002) 360(9335):806.
   Google Scholar
• MASON BW, HOWARD AJ, MAGEE JT: Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob. Chemother. (2003) 51(4):1033-1036.
   Google Scholar
• NISHIJIM S, OHSHIMA S, HIGASHIDA T, NAKAYA H, KUROKAWA I: Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000. Int. J. Dermatol. (2003) 42(1):23-25.
   PubMedGoogle Scholar
• RAVENSCROFT JC, LAYTON A, BARNHAM M: Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin. Exp. Dermatol. (2000) 25(4):327-330.
   PubMed Web of Science ®Google Scholar
• SHAH M, MOHANRAJ M: High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br. J. Dermatol. (2003) 148(5):1018-1020.
   PubMed Web of Science ®Google Scholar
• PEETERS KA, MASCINI EM, SANDERS CJ: Resistance of Staphylococcus aureus to fusidic acid. Int. J. Dermatol. (2004) 43(3):235-236.
   PubMed Web of Science ®Google Scholar
• BROWN EM, THOMAS P: Fusidic acid resistance in Staphylococcus aureus isolates. Lancet (2002) 359(9308):803.
   PubMed Web of Science ®Google Scholar
• ROBERTS SM, FREEMAN AF, HARRINGTON SM et al.: Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J. (2006) 25(6):562-564.
   PubMed Web of Science ®Google Scholar
• KELLY S, COLLINS J, DAVIN M, GOWING C, MURPHY PG: Linezolid resistance in coagulase-negative staphylococci. J. Antimicrob. Chemother. (2006) MORE INFO
   Google Scholar
• GALES AC, SADER HS, ANDRADE SS et al.: Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents (2006) 27(4):300-302.
   PubMed Web of Science ®Google Scholar
• HIRSCHWERK D, GINOCCHIO CC, BYTHROW M, CONDON S: Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. (2006) 27(3):315-317.
   PubMed Web of Science ®Google Scholar
• SKIEST DJ: Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. (2006) 44(2):655-656.
   PubMed Web of Science ®Google Scholar
• MARTY FM, YEH WW, WENNERSTEN CB et al.: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. (2006) 44(2):595-597.
   PubMed Web of Science ®Google Scholar
• PHONGSAMART W, SRIFEUNGFUNG S, TIENSASITORN C et al.: The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand. J. Med. Assoc. Thai. (2005) 88(Suppl. 8):S264-S268.
   Google Scholar
• APPELBAUM PC: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. (2006) 12(Suppl. 1):16-23.
   PubMed Web of Science ®Google Scholar